Caused by the coronavirus, SARS-CoV-2, Coronavirus Disease (COVID-19) is known to have particularly deleterious effects on those with underlying conditions such as cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), hypertension (HTN) and diabetes mellitus (DM).
In the general population, some infected patients remain asymptomatic while others can experience mild to moderate respiratory illness, digestive disturbance, and death in severe cases. Shortly after the World Health Organization (WHO) declared the disease a pandemic in March 2020, WHF launched a Global Study on CVD and COVID-19 whose aims are:
- To describe cardiovascular outcomes among patients hospitalized with COVID-19;
- To identify cardiovascular risk factors associated with poor in-hospital prognosis among patients with COVID-19.
As the largest global effort to reflect geographic spread, the data is expected to add to our understanding of disease progression in particularly hard-hit areas of society and the associated medical and social burden. In addition, it will also hopefully inform approaches in clinical practice, health policy and pandemic preparedness. As outlined in the study protocol, “by providing comparable data from countries around the globe, the study will inform the delivery of care for patients with COVID19, with underlying cardiovascular conditions or with cardiovascular complications.”
At the end of the study, an assessment and analysis will be prepared capturing results and methodology which underwent editorial review. The product will be shared in relevant outlets including WHF’s open access Global Heart Journal; related outputs are expected to include a WHF position statement on COVID vaccines, feature articles and recommendations and insights to support clinical and policy work.